Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Enters Mutation Discovery Partnership with Novartis

NEW YORK, Dec. 2 (GenomeWeb News) - Transgenomic today said that it has entered into "several specific agreements" with Novartis Pharmaceuticals to provide mutation discovery services to support translational research programs in oncology.

Transgenomic said that the goal of the collaboration is to support biomarker discovery efforts in clinical trials by identifying genetic mutations that correlate with patients' response or responses to cancer therapeutics. Transgenomic said it has already performed proof-of-principle work and begun to deliver data for the projects.

The companies have several specific project agreements, according to Transgenomic, including a clinical assay/protocol development project.

"Novartis Oncology is dedicated to incorporating knowledge of genomic changes associated with cancer into the drug development process," said Kenneth Culver, global head of translational medicine at Novartis Oncology. He added that the company is using Transgenomic's WAVE technology to detect low-abundance mutations in clinical specimens, and to scan for mutations "rather than develop specific assays for each potential mutation."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.